| SEC entity type | operating | 2026-11-19 | SEC EDGAR company profile | 2026-11-21 11:41 UTC | Report an error |
|---|
| SIC industry | 2834 Pharmaceutical Preparations | 2026-11-19 | SEC EDGAR company profile | 2026-11-21 11:41 UTC | Report an error |
|---|
| State of incorporation | V8 | 2026-11-19 | SEC EDGAR company profile | 2026-11-21 11:41 UTC | Report an error |
|---|
| Fiscal year end (MMDD) | 1231 | 2026-11-19 | SEC EDGAR company profile | 2026-11-21 11:41 UTC | Report an error |
|---|
| Business address | BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES, V8, 1066 | 2026-11-19 | SEC EDGAR company profile | 2026-11-21 11:41 UTC | Report an error |
|---|
| Exchanges | NYSE | 2026-11-19 | SEC EDGAR company profile | 2026-11-21 11:41 UTC | Report an error |
|---|
| Revenue (fiscal year ended 2025-12-31) | $81,357,000 | 2025-12-31 | 10-K, XBRL Revenues | 2026-11-21 11:41 UTC | Report an error |
|---|
| Net income (loss) (fiscal year ended 2025-12-31) | $-142,623,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | 2026-11-21 11:41 UTC | Report an error |
|---|
| Total assets (at 2025-12-31) | $323,150,000 | 2025-12-31 | 10-K, XBRL Assets | 2026-11-21 11:41 UTC | Report an error |
|---|
| Stockholders' equity (at 2025-12-31) | $-185,834,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | 2026-11-21 11:41 UTC | Report an error |
|---|
| Cash and cash equivalents (at 2025-12-31) | $261,338,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | 2026-11-21 11:41 UTC | Report an error |
|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $-141,174,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | 2026-11-21 11:41 UTC | Report an error |
|---|
| Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31) | $264,000 | 2025-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | 2026-11-21 11:41 UTC | Report an error |
|---|
| Operating lease liabilities (at 2025-12-31) | $1,573,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09) | On November 9, 2026, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the third quarter ended September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall… | 2026-11-09 | SEC EDGAR 8-K 0001628280-26-071899 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 2.02, Results of Operations and Financial (filed 2026-11-04) | Condition. | 2026-11-04 | SEC EDGAR 8-K 0000950103-26-016945 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 7.01, Regulation FD Disclosure (filed 2026-11-04) | On November 4, 2026, ADC Therapeutics SA (the “Company”) issued a press release and made available a presentation in connection with new and updated data from ZYNLONTA clinical trials which will be shared across multiple abstracts, including five oral presentations, at the 68th American Society of Hematology (ASH) Annual Meeting taking place December 12–15, 2026, in New Orleans, Louisiana, copies of which are attached as Exhibit 99.1 and Exhibit 99.2, respectively, to this Current Report on Form 8-K and incorporated by reference herein. The presentation includes preliminary revenue estimates for three and nine months ended September 30, 2026, and preliminary cash and cash equivalents as of… | 2026-11-04 | SEC EDGAR 8-K 0000950103-26-016945 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 8.01, Other Events (filed 2026-11-04) | On November 4, 2026, the Company announced updated data from an abstract at ASH for the LOTIS-7 Phase 1b trial of ZYNLONTA in combination with glofitamab in relapsed or refractory large B cell lymphoma. As of the June 15, 2026 data cutoff date, at the ZYNLONTA 150 µg/kg starting dose + glofitamab: • Patients had received a median of one prior treatment (range: 1-5); 52.4% (n=54) of patients had primary refractory disease. • Among 97 efficacy-evaluable patients, the overall response rate (“ORR”) was 88.7% (n=86) and the complete response rate (“CRR”) was 75.3% (n=73). o 2.1% (n=2) of patients achieved stable disease. o 28 patients converted to complete responses over time, from stable… | 2026-11-04 | SEC EDGAR 8-K 0000950103-26-016945 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 1.01, Entry into a Material Definitive Agreement (filed 2026-10-13) | Private Placement On October 7, 2026, ADC Therapeutics SA (the “Company”) entered into securities purchase agreements for the sale of its equity securities to certain institutional investors in a $86.6 million (assuming the cash exercise of the pre-funded warrants) private placement (the “Private Placement”). In the private placement, the Company will sell 12,911,347 common shares at $1.4200 per share and pre-funded warrants to purchase 48,088,653 common shares at $1.32400 per pre-funded warrant, which is the price per common share in the private placement minus the exercise price per pre-funded warrant. The private placement is expected to close on October 22, 2026, subject to customary… | 2026-10-13 | SEC EDGAR 8-K 0000950103-26-015465 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-10-13) | On October 8, 2026, the Company issued a press release that includes the preliminary net product revenues from sales of ZYNLONTA for the quarter ended September 30, 2026 and the preliminary cash and cash equivalents as of September 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The ZYNLONTA net product revenues and cash and cash equivalents figures are preliminary and unaudited and reflect the Company’s estimated financial results. In preparing this information, management made a number of complex and subjective judgments and estimates about the appropriateness of certain reported amounts and… | 2026-10-13 | SEC EDGAR 8-K 0000950103-26-015465 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 3.02, Unregistered Sales of Equity Securities (filed 2026-10-13) | The information set forth under Item 1.01 of this Current Report on Form 8-K with regards to the Private Placement, the Lender Warrants and the HCR Warrants is incorporated by reference in this | 2026-10-13 | SEC EDGAR 8-K 0000950103-26-015465 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 2.02, Results of Operations and Financial (filed 2026-08-13) | Condition. On August 13, 2026, ADC Therapeutics SA (the “Company”) issued a press release announcing the Company’s financial results for the three and six months ended June 30, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in this Item 2.02 and Exhibit 99.1 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act… | 2026-08-13 | SEC EDGAR 8-K 0000950103-26-012287 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| 8-K Item 7.01, Regulation FD Disclosure (filed 2026-08-13) | On August 13, 2026, the Company made available a presentation, a copy of which is attached as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein. The information contained in this Item 7.01 and Exhibit 99.2 shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. | 2026-08-13 | SEC EDGAR 8-K 0000950103-26-012287 (text as filed, excerpt) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #1 (13F as filed): Nantahala Capital Management, LLC | $26,378,034 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #2 (13F as filed): Redmile Group, LLC | $12,333,580 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #3 (13F as filed): TCG Crossover Management, LLC | $12,187,487 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #4 (13F as filed): Prosight Management, LP | $8,372,481 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #5 (13F as filed): BlackRock, Inc. | $7,511,500 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #6 (13F as filed): Point72 Asset Management, L.P. | $3,904,584 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #7 (13F as filed): MILLENNIUM MANAGEMENT LLC | $3,102,502 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #8 (13F as filed): CITADEL ADVISORS LLC | $2,197,048 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #9 (13F as filed): GOLDMAN SACHS GROUP INC | $2,048,434 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|
| Largest institutional holder #10 (13F as filed): STATE STREET CORP | $1,803,845 | 2026-06-30 | SEC Form 13F data sets (quarterly; holdings as filed) | 2026-11-21 11:41 UTC | Report an error |
|---|